drugset
drugset / Trial / NCT01743859

Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

NCT01743859 ↗

Phase 2 Completed 37 enrolled University of Colorado, Denver Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the complete remission/complete remission with incomplete recovery of blood counts (CR/CRi) rate for relapsed and refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients.

Timeline

Start
2012-12-06
Primary completion
2016-04-27
Completion
2016-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Lenalidomide Other / unclassified 50 mg Oral

Indications

acute myeloid leukemia